Kambham Neeraja, Kong Christina, Longacre Teri A, Natkunam Yasodha
Department of Pathology, Stanford University School of Medicine, CA 94305, USA.
Appl Immunohistochem Mol Morphol. 2005 Dec;13(4):304-10. doi: 10.1097/01.pai.0000159773.50905.7b.
Syndecan-1, a heparan sulfate-rich membrane glycoprotein, is expressed in plasma cells and is considered a reliable marker of plasmacytic differentiation. However, it has not been widely tested in non-hematolymphoid tissues, and thus its utility in the setting of an undifferentiated malignant neoplasm has not been evaluated. The authors conducted an extensive study of CD138 staining in over 1,700 normal, benign, and malignant non-hematolymphoid tissues, using five tissue microarrays. Immunohistochemical staining was performed with two commercially available CD138 monoclonal antibodies directed against syndecan-1 (Serotec, Oxford, UK, and DAKO, Carpenteria, CA). In addition to the specific membrane staining, many normal tissues and epithelial tumors showed strong cytoplasmic immunoreactivity. A small subset of mesenchymal neoplasms also showed membrane and cytoplasmic immunoreactivity. In squamous cell carcinoma of the head and neck, renal cell carcinoma, and prostate adenocarcinoma, the intensity of CD138 staining inversely correlated with the histologic grade of the carcinoma. However, statistically significant staining differences and their correlation with histologic grades differed depending on whether the Serotec or the DAKO antibody was used. These results indicate that CD138 immunoreactivity is widespread in normal and neoplastic epithelial tissues, as well as a variety of undifferentiated epithelial and mesenchymal processes. The authors conclude that the expression of syndecan-1, although relatively specific to plasma cells within the hematolymphoid system, should be interpreted with extreme caution in the setting of an undifferentiated neoplasm. Furthermore, the two commercially available monoclonal CD138 antibodies tested in this study showed significant differences in their immunoreactivity in different tumor types.
Syndecan-1是一种富含硫酸乙酰肝素的膜糖蛋白，在浆细胞中表达，被认为是浆细胞分化的可靠标志物。然而，它尚未在非血液淋巴组织中广泛测试，因此其在未分化恶性肿瘤中的效用尚未得到评估。作者使用五个组织微阵列，对1700多个正常、良性和恶性非血液淋巴组织中的CD138染色进行了广泛研究。使用两种针对syndecan-1的市售CD138单克隆抗体（英国牛津的Serotec和加利福尼亚卡彭特里亚的DAKO）进行免疫组织化学染色。除了特异性膜染色外，许多正常组织和上皮肿瘤还显示出强烈的细胞质免疫反应性。一小部分间叶性肿瘤也显示出膜和细胞质免疫反应性。在头颈部鳞状细胞癌、肾细胞癌和前列腺腺癌中，CD138染色强度与癌的组织学分级呈负相关。然而，根据使用的是Serotec抗体还是DAKO抗体，统计学上显著的染色差异及其与组织学分级的相关性有所不同。这些结果表明，CD138免疫反应性在正常和肿瘤上皮组织以及各种未分化的上皮和间叶过程中广泛存在。作者得出结论，syndecan-1的表达虽然在血液淋巴系统内相对特异于浆细胞，但在未分化肿瘤的情况下应极其谨慎地解释。此外，本研究中测试的两种市售单克隆CD138抗体在不同肿瘤类型中的免疫反应性存在显著差异。
